acute ischemic stroke
Conditions
Interventions
case series:Reperfusion treatment
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. Acute ischemic stroke; 3. NIHSS score >=4 points at the time of enrollment; 4. Intracranial artery occlusion (TIMI grade 0-1): internal carotid artery (T/L), middle cerebral artery M1/M2 segment, anterior cerebral artery A1/A2 segment, basilar artery, vertebral artery; 5. Plan reperfusion therapy including intravenous thrombolysis, arterial thrombolysis, mechanical thrombectomy, angioplasty, etc.; 6. The patient or the patient's legal representative is able and willing to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. The mRS score before the stroke was >1; 2. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc.; 3. History of coagulation disorders, systemic bleeding, thrombocytopenia or neutropenia; 4. Chronic liver disease, liver and kidney insufficiency, elevated ALT (more than 3 times the upper limit of normal), elevated serum creatinine (more than 2 times the upper limit of normal); 5. Those with serious cardiopulmonary diseases, the researchers believe that they are not suitable to participate in this study; 6. Patients with life expectancy less than 3 months or unable to complete the study for other reasons; 7. DSA examination is contraindicated, severe contrast medium allergy or iodine contrast medium is absolutely contraindicated; 8. Patients of childbearing age, pregnant or breastfeeding women who have a negative pregnancy test but refuse to take effective contraceptive measures; 9. Unable to complete the researcher due to mental illness, cognitive or emotional disorder; 10. Patients who are considered by other researchers to be unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Onset-reperfusion time;Functional independence (defined as Mrs<= 2) or functional improvement (mRS rank variable analysis) at 90 days;Proportion of serious adverse events occurring within 90±7 days of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time from onset to hospital admission;Admission - opening Hours;Admission-imaging time;Imaging-puncture time;Puncture-opening time;Changes of NIHSS score immediately after reperfusion;Changes of NIHSS score 24 ± 3 hours after reperfusion;Arterial recanalization ratio 24 +/- 3 hours after reperfusion;Changes of cerebral infarction volume on plain CT scan 24 +/- 3 hours after reperfusion;Changes of NIHSS score 7 days after reperfusion or at discharge;Changes of NIHSS at 90 +/- 7 days;Quality of life at 90 +/- 7 days;The proportion of symptomatic bleeding within 90 +/- 7 days of treatmen;The proportion of all-cause death within 90 +/- 7 days of treatment;Proportion of adverse events within 90 +/- 7 days of treatment;Proportion of serious adverse events within 14 days of treatment;Proportion of all-cause death within 14 days of treatment;Proportion of adverse events within 14 days of treatment; | — |
Countries
China
Contacts
Public ContactWu Wei
Qilu Hospital of Shandong University
Outcome results
None listed